INCA035784 not checked

Incyte Corporation

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“INCA035784 will be administered at the assigned dose in the dose escalation part and at the protocol defined dose in the dose expansion part.”In the company’s words, NCT07008118 on ClinicalTrials.gov
Tested for
Myeloproliferative Neoplasms
Main trialPhase 1
“This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.”In the company’s words, NCT07008118 on ClinicalTrials.gov

Other drugs for Myeloproliferative Neoplasms

All 68 drugs for Myeloproliferative Neoplasms

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 14 Mar 2028 A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow INCA035784

Following is part of Solo: you see every change to INCA035784 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in